No Data
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $12
Sector Update: Health Care Stocks Lower Monday Afternoon
Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Rezolute (RZLT)
Rezolute Announces FDA Granted BTD to Ersodetug
Rezolute: FDA Grants Breakthrough Therapy Designation To Investigational Therapy, Ersodetug, For Treatment Of Hypoglycemia Caused By Tumor HI
Express News | Rezolute Inc - Registrational Study of Ersodetug to Start Mid-2025